These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29233215)

  • 21. Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein.
    Janowska MK; Wu KP; Baum J
    Sci Rep; 2015 Oct; 5():15164. PubMed ID: 26477939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein.
    Meade RM; Morris KJ; Watt KJC; Williams RJ; Mason JM
    J Mol Biol; 2020 Dec; 432(24):166706. PubMed ID: 33186583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A glimpse into the structural properties of α-synuclein oligomers.
    Santos J; Pallarès I; Ventura S
    Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture.
    Rutherford NJ; Giasson BI
    Neurosci Lett; 2015 Jun; 597():43-8. PubMed ID: 25892596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of α-synuclein with biomembranes in Parkinson's disease--role of cardiolipin.
    Ghio S; Kamp F; Cauchi R; Giese A; Vassallo N
    Prog Lipid Res; 2016 Jan; 61():73-82. PubMed ID: 26703192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioinorganic Chemistry of Parkinson's Disease: Affinity and Structural Features of Cu(I) Binding to the Full-Length β-Synuclein Protein.
    Miotto MC; Pavese MD; Quintanar L; Zweckstetter M; Griesinger C; Fernández CO
    Inorg Chem; 2017 Sep; 56(17):10387-10395. PubMed ID: 28820253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide.
    Mohammadi S; Nikkhah M; Hosseinkhani S
    Protein Pept Lett; 2017; 24(8):757-764. PubMed ID: 28820063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fundamental mechanisms of amyloid fibril formation by alpha-synuclein in Parkinson's disease: quantitative modelling].
    Galvagnion C; Buell AK
    Med Sci (Paris); 2015; 31(6-7):597-600. PubMed ID: 26152159
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of the α-Synuclein Initial Ensemble Structure on Fibrillation Pathways and Kinetics.
    Bai J; Cheng K; Liu M; Li C
    J Phys Chem B; 2016 Mar; 120(12):3140-7. PubMed ID: 26950519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 14-3-3τ as a Modulator of Early α-Synuclein Multimerization and Amyloid Formation.
    Heesink G; van den Oetelaar MCM; Semerdzhiev SA; Ottmann C; Brunsveld L; Blum C; Claessens MMAE
    ACS Chem Neurosci; 2024 May; 15(9):1926-1936. PubMed ID: 38635928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the effect of methionine oxidation on the interplay between α-synuclein and synaptic-like vesicles.
    Uceda AB; Frau J; Vilanova B; Adrover M
    Int J Biol Macromol; 2023 Feb; 229():92-104. PubMed ID: 36584779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational Study on the Role of γ-Synuclein in Inhibiting the α-Synuclein Aggregation.
    Sanjeev A; Mattaparthi VSK
    Cent Nerv Syst Agents Med Chem; 2019; 19(1):24-30. PubMed ID: 30318002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein.
    Leitao A; Bhumkar A; Hunter DJB; Gambin Y; Sierecki E
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruptive membrane interactions of alpha-synuclein aggregates.
    Iyer A; Claessens MMAE
    Biochim Biophys Acta Proteins Proteom; 2019 May; 1867(5):468-482. PubMed ID: 30315896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
    Takahashi R; Ono K; Takamura Y; Mizuguchi M; Ikeda T; Nishijo H; Yamada M
    J Neurochem; 2015 Sep; 134(5):943-55. PubMed ID: 26016728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Analysis of α-Synuclein Amyloid Formation and Cross-Reactivity.
    Horvath I; Rocha S; Wittung-Stafshede P
    Methods Mol Biol; 2018; 1779():73-83. PubMed ID: 29886528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synuclein Family Members Prevent Membrane Damage by Counteracting α-Synuclein Aggregation.
    Scheibe C; Karreman C; Schildknecht S; Leist M; Hauser K
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative.
    Chau E; Kim H; Shin J; Martinez A; Kim JR
    Biochem Biophys Res Commun; 2021 Oct; 574():85-90. PubMed ID: 34454326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane Remodeling and Stimulation of Aggregation Following α-Synuclein Adsorption to Phosphotidylserine Vesicles.
    Hoover BM; Shen Z; Gahan CG; Lynn DM; Van Lehn RC; Murphy RM
    J Phys Chem B; 2021 Feb; 125(6):1582-1594. PubMed ID: 33538595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biophysical properties and cellular toxicity of covalent crosslinked oligomers of α-synuclein formed by photoinduced side-chain tyrosyl radicals.
    Borsarelli CD; Falomir-Lockhart LJ; Ostatná V; Fauerbach JA; Hsiao HH; Urlaub H; Paleček E; Jares-Erijman EA; Jovin TM
    Free Radic Biol Med; 2012 Aug; 53(4):1004-15. PubMed ID: 22771470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.